Published in Gene Therapy Weekly, February 16th, 2006
Two of the grants fund early stage clinical trials that are testing new therapeutic strategies in ALS patients. These trials must now be approved by the U.S. Food and Drug Administration (FDA) before proceeding to enroll patients. A third grant allows investigators to produce a test to show whether a candidate treatment is affecting the targeted aspect of the disease process.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.